Aberrant expression and clinical importance of the microRNAs regulated by p53 in lymphocytes
| miRNAs . | Genes . | Locus . | Targets . | Aberrant expression . | Clinical importance . |
|---|---|---|---|---|---|
| miR-15-a | MIR15A | 13q14.2 | MYB; BCL2; MCL1 | Loss or reduced in CLL | Associated with CLL pathogenesis: del13q14 is in 55% CLL |
| miR-16-1 | MIR16-1 | 13q14.2 | MYB; BCL2; MCL1 | Loss or reduced in CLL | Associated with CLL pathogenesis: del13q14 is in 55% CLL |
| miR-34a | MIR34A | 1p36.22 | FOXP1; BCL2 | Reduced in DLBCL and CLL | Block pro-B to pre-B development; as a tumor suppressor in CLL mouse model; reduced miR-34a expression correlated with inferior OS in DLBCL and CLL |
| miR-34b | MIR34B | 11q23.1 | ZAP70 | Loss or reduced in CLL | Associated with CLL pathogenesis: del11q is in 18% CLL |
| miR-34c | MIR34C | 11q23.1 | ZAP70 | Loss or reduced in CLL | Associated with CLL pathogenesis: del11q is in 18% CLL |
| let-7 family | |||||
| let-7a | MIRLET7A1 | 9q22.32 | RAS | Reduced in CLL | |
| let-7b | MIRLET7B | 22q13.31 | RAS | ||
| let-7c | MIRLET7C | 21q21.1 | RAS | ||
| let-7d | MIRLET7D | 9q22.32 | RAS | Predicted higher risk in SS | |
| let-7e | MIRLET7E | 19q13.41 | RAS | Reduced in DLBCL | |
| let-7f | MIRLET7F1 | 9q22.32 | RAS | Predicted higher risk in SS | |
| let-7g | MIRLET7G | 3p21.1 | RAS | Differential in DLBCL | Reduced expression correlated with longer EFS in DLBCL |
| let-7i | MIRLET7I | 12q14.1 | RAS | Predicted higher risk in SS | |
| miR-17–92 cluster | |||||
| miR-17-3p | MIR17 | 13q31.3 | BIM; p21 | Up-regulation correlated with worse clinical outcome in SS | |
| miR-17-5p | MIR17 | 13q31.3 | PTEN; BIM; p21; E2F1; CCND1 | High in DLBCL; differential in CLL | |
| miR-19a | MIR19A | 13q31.3 | PTEN; BIM; p21; SOCS1 | Overexpressed in MM | Reduced miR-19a correlated with shorter EFS in DLBCL |
| miR-19b-1 | MIR19B1 | 13q31.3 | PTEN; BIM; p21 | Overexpressed in MM | |
| miR-18a | MIR18 | 13q31.3 | BIM; p21 | ||
| miR-21 | MIR21 | 17q23.1 | PTEN; PDCD4; SPRY2 | Up-regulated in DLBCL and FL | Decreased expression correlated with poor OS in DLBCL |
| Overexpressed in MM | Up-regulation predicted unfavorable clinical outcome in SS | ||||
| Overexpressed in NK-cell lymphoma | |||||
| miR-142-3p | MIR142 | 17q22 | miR-142 /c-myc fusion gene overexpressed in B-cell lymphomas | ||
| miR-142-5p | MIR142 | 17q22 | |||
| miR-143 | MIR143 | 5q32 | Up-regulated in DLBCL and FL | ||
| Low in BL | |||||
| miR-145 | MIR145 | 5q32 | Down-regulated in DLBCL | ||
| Up-regulated in DLBCL and FL | |||||
| Low in BL | |||||
| miR-155 | MIR155 | 21q21.3 | SHIP1; SOCS1 | High in CLL and DLBCL | |
| Overexpressed in NK-cell lymphoma | |||||
| miR-192 | MIR192 | 11q13.1 | MDM2; IGF1R; IGF1 | Down-regulated in MM | |
| miR-194-1 | MIR194-1 | 1q41 .1 | MDM2 | Down-regulated in MM | |
| miR-194-2 | MIR194-2 | 11q13.1 | MDM2 | Down-regulated in MM | |
| miR-215 | MIR215 | 1q41 .1 | MDM2;IGF1R; IGF1 | Down-regulated in MM |
| miRNAs . | Genes . | Locus . | Targets . | Aberrant expression . | Clinical importance . |
|---|---|---|---|---|---|
| miR-15-a | MIR15A | 13q14.2 | MYB; BCL2; MCL1 | Loss or reduced in CLL | Associated with CLL pathogenesis: del13q14 is in 55% CLL |
| miR-16-1 | MIR16-1 | 13q14.2 | MYB; BCL2; MCL1 | Loss or reduced in CLL | Associated with CLL pathogenesis: del13q14 is in 55% CLL |
| miR-34a | MIR34A | 1p36.22 | FOXP1; BCL2 | Reduced in DLBCL and CLL | Block pro-B to pre-B development; as a tumor suppressor in CLL mouse model; reduced miR-34a expression correlated with inferior OS in DLBCL and CLL |
| miR-34b | MIR34B | 11q23.1 | ZAP70 | Loss or reduced in CLL | Associated with CLL pathogenesis: del11q is in 18% CLL |
| miR-34c | MIR34C | 11q23.1 | ZAP70 | Loss or reduced in CLL | Associated with CLL pathogenesis: del11q is in 18% CLL |
| let-7 family | |||||
| let-7a | MIRLET7A1 | 9q22.32 | RAS | Reduced in CLL | |
| let-7b | MIRLET7B | 22q13.31 | RAS | ||
| let-7c | MIRLET7C | 21q21.1 | RAS | ||
| let-7d | MIRLET7D | 9q22.32 | RAS | Predicted higher risk in SS | |
| let-7e | MIRLET7E | 19q13.41 | RAS | Reduced in DLBCL | |
| let-7f | MIRLET7F1 | 9q22.32 | RAS | Predicted higher risk in SS | |
| let-7g | MIRLET7G | 3p21.1 | RAS | Differential in DLBCL | Reduced expression correlated with longer EFS in DLBCL |
| let-7i | MIRLET7I | 12q14.1 | RAS | Predicted higher risk in SS | |
| miR-17–92 cluster | |||||
| miR-17-3p | MIR17 | 13q31.3 | BIM; p21 | Up-regulation correlated with worse clinical outcome in SS | |
| miR-17-5p | MIR17 | 13q31.3 | PTEN; BIM; p21; E2F1; CCND1 | High in DLBCL; differential in CLL | |
| miR-19a | MIR19A | 13q31.3 | PTEN; BIM; p21; SOCS1 | Overexpressed in MM | Reduced miR-19a correlated with shorter EFS in DLBCL |
| miR-19b-1 | MIR19B1 | 13q31.3 | PTEN; BIM; p21 | Overexpressed in MM | |
| miR-18a | MIR18 | 13q31.3 | BIM; p21 | ||
| miR-21 | MIR21 | 17q23.1 | PTEN; PDCD4; SPRY2 | Up-regulated in DLBCL and FL | Decreased expression correlated with poor OS in DLBCL |
| Overexpressed in MM | Up-regulation predicted unfavorable clinical outcome in SS | ||||
| Overexpressed in NK-cell lymphoma | |||||
| miR-142-3p | MIR142 | 17q22 | miR-142 /c-myc fusion gene overexpressed in B-cell lymphomas | ||
| miR-142-5p | MIR142 | 17q22 | |||
| miR-143 | MIR143 | 5q32 | Up-regulated in DLBCL and FL | ||
| Low in BL | |||||
| miR-145 | MIR145 | 5q32 | Down-regulated in DLBCL | ||
| Up-regulated in DLBCL and FL | |||||
| Low in BL | |||||
| miR-155 | MIR155 | 21q21.3 | SHIP1; SOCS1 | High in CLL and DLBCL | |
| Overexpressed in NK-cell lymphoma | |||||
| miR-192 | MIR192 | 11q13.1 | MDM2; IGF1R; IGF1 | Down-regulated in MM | |
| miR-194-1 | MIR194-1 | 1q41 .1 | MDM2 | Down-regulated in MM | |
| miR-194-2 | MIR194-2 | 11q13.1 | MDM2 | Down-regulated in MM | |
| miR-215 | MIR215 | 1q41 .1 | MDM2;IGF1R; IGF1 | Down-regulated in MM |
SS indicates Sézary syndrome; and EFS, event-free survival.